We are dedicated to providing novel science, improved clinical outcomes and a compelling value proposition to key stakeholders around the world. We have taken our knowledge of epigenetics and, through the mechanism of selective BET inhibition, applied it to targeted high-risk cardiovascular and diabetes patients that are a leading cost driver patient segment to health systems globally. One of our key tenets is to provide a complete solution to key pharmaceutical partners that will drive innovation, strong clinical efficacy and robust health value for reimbursement programs. We learned from our recent BETonMACE Phase 3 program key observations such as:
- Statistically significant risk reduction of combined Primary MACE and Hospitalization for Heart Failure
- Statistically significant reduction in Primary MACE among enhanced-risk Stage 3 CKD patients
- Statistically significant improvement of Cognition using MoCA scoring in those with highest risk, those with baseline MoCA below 22
- Enhanced statistical improvement and synergy in MACE reduction when targeting patients using new oral agents for diabetes such as DPP4s and SGLT2s
These current learnings are being applied to our therapeutic product position which will further refine the opportunity for regulatory bodies such as FDA, and potential pharma partners with the goal to improve apabetalone’s value proposition within health systems.
Shenzhen Hepalink Pharmaceutical Co., Ltd.
In April 2015, Resverlogix and Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Hepalink”), a leading global life science company, entered into one of the largest ever strategic partnerships for a single molecule – apabetalone (RVX-208) – in high-risk cardiovascular disease patients, including those with diabetes and chronic kidney disease (“CKD”). A definitive agreement was completed in July 2015 where Resverlogix is eligible to receive sales-based milestone and royalty payments.
Medison Pharma Ltd.
On January 08, 2018, Resverlogix entered into a licensing agreement with Medison Pharma Ltd. (“Medison”) for apabetalone in Israel and the Palestine Authority. Under the terms of the agreement, Medison has the exclusive rights to distribute and market apabetalone in Israel. Medison will be responsible for all regulatory, sales and marketing costs for apabetalone in the Israel region.
We are currently focused on bringing apabetalone to market for three key indications: high risk cardiovascular disease & diabetes, chronic kidney disease, and neurodegeneration / dementia. We continue to pursue additional opportunities for collaboration in the fields of muscular dystrophy, pulmonary arterial hypertension, neurofibromatosis and other orphan diseases.